Amgen Inc
NASDAQ:AMGN
Intrinsic Value
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. [ Read More ]
The intrinsic value of one
AMGN
stock under the Base Case scenario is
200.3
USD.
Compared to the current market price of 268.76 USD,
Amgen Inc
is
Overvalued by 25%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access Amgen Inc's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
Amgen Inc
| Current Assets | 47.4B |
| Cash & Short-Term Investments | 34.2B |
| Receivables | 5.8B |
| Other Current Assets | 7.3B |
| Non-Current Assets | 42.9B |
| PP&E | 5.5B |
| Intangibles | 30.2B |
| Other Non-Current Assets | 7.2B |
| Current Liabilities | 17.1B |
| Accounts Payable | 1.2B |
| Accrued Liabilities | 13.7B |
| Other Current Liabilities | 2.2B |
| Non-Current Liabilities | 66.4B |
| Long-Term Debt | 59.4B |
| Other Non-Current Liabilities | 7B |
AMGN Profitability Score
Profitability Due Diligence
Amgen Inc's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
Score
Amgen Inc's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
AMGN Solvency Score
Solvency Due Diligence
Amgen Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Amgen Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMGN Price Targets Summary
Amgen Inc
According to Wall Street analysts, the average 1-year price target for
AMGN
is 260.25 USD
with a low forecast of 176.75 USD and a high forecast of 325.5 USD.
Ownership
AMGN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
AMGN Price
Amgen Inc
| Average Annual Return | 5.61% |
| Standard Deviation of Annual Returns | 16.05% |
| Max Drawdown | -25% |
| Market Capitalization | 144B USD |
| Shares Outstanding | 538 000 000 |
| Percentage of Shares Shorted | 1.16% |
AMGN News
Last Video News
Amgen Inc
Last Important Events
Amgen Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Amgen Inc
Company Profile
Amgen Inc
Country
Industry
Market Cap
Dividend Yield
Description
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 24,200 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company operates in human therapeutics segment. Its marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The firm focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
Contact
IPO
Employees
Officers
The intrinsic value of one
AMGN
stock under the Base Case scenario is
200.3
USD.
Compared to the current market price of 268.76 USD,
Amgen Inc
is
Overvalued by 25%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
